College ter Beoordeling van Geneesmiddelen / Medicines Evaluation Board

Graadt van Roggenweg 500
3531 AH Utrecht
The Netherlands

MUTUAL RECOGNITION PROCEDURE

PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

Octacillin, 800 mg/g powder for oral solution for chickens

Created: March 2014

Updated: August 2021

MODULE 1

PRODUCT SUMMARY

EU Procedure number	NL/V/0144/001/MR
Name, strength and pharmaceutical form	Octacillin, 800 mg/g, powder for oral solution.
Applicant	Eurovet Animal Health B.V. Handelsweg 25 5531 AE Bladel the Netherlands
Active substance(s)	Amoxicillin trihydrate
ATC Vetcode	QJ01CA
Target species	Chickens
Indication for use	Where clinical disease is present in the flock, treatment and prevention of respiratory or gastrointestinal disease due to pathogens sensitive to amoxicillin.

MODULE 2

The Summary of Product Characteristics (SPC) for this product is available on the Heads of Veterinary Medicines Agencies website (http://www.HMA.eu).

MODULE 3

PUBLIC ASSESSMENT REPORT

Legal basis of original application	Generic application in accordance with Article 13(1) of Directive 2001/82/EC as amended.
Date of completion of the original mutual recognition procedure	24 February 2010
Date product first authorised in the Reference Member State (MRP only)	15 October 2009
Concerned Member States for original procedure	DE, FR.

I. SCIENTIFIC OVERVIEW

The product is produced and controlled using validated methods and tests, which ensure the consistency of the product released on the market.

The safety and efficacy aspects of Octacillin, 800 mg/g, powder for oral solution for chicken are based on demonstrated bioequivalence with the Dutch European reference product Paracilline Oplosbaar Poeder (REG NL 4256).

The product is safe for the user, the consumer of foodstuffs from treated animals and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.
The efficacy of the product was demonstrated according to the claims made in the SPC.

The overall risk/benefit analysis is in favour of granting a marketing authorisation.

II. QUALITY ASPECTS

A. Composition

The product contains amoxicillin trihydrate at 800 milligram per gram (corresponding to 697 mg/g amoxicillin) and excipients sodium carbonate monohydrate, sodium citrate and silica colloidal anhydrous.

The product is packed in sachets consisting of different layers of aluminium and polyethylene. The particulars of the containers and controls performed are provided and conform to the regulation.

The choice of the formulation and absence of preservative are justified.

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

B. Method of Preparation of the Product

The product is manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site.

Process validation data on the product have been presented in accordance with the relevant European guidelines.

C. Control of Starting Materials

The active substance is amoxicillin trihydrate, an established substance described in the European Veterinary Pharmacopoeia. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

Three active substance suppliers are used, a Certificate of Suitability (CEP) has been provided for all three.

D. Specific Measures concerning the Prevention of the Transmission of Animal Spongiform Encephalopathies

There are no substances within the scope of the TSE Guideline present or used in the manufacture of this product.

E. Control on intermediate products

Not applicable.

F. Control Tests on the Finished Product

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product.

Satisfactory validation data for the analytical methods have been provided.

Batch analytical data from the proposed production site have been provided demonstrating compliance with the specification.

G. Stability

Stability data on the active substance have been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions.

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life when stored under the approved conditions.

H. Genetically Modified Organisms

Not applicable.

J. Other Information

None.

III. SAFETY AND RESIDUES ASSESSMENT (PHARMACO-TOXICOLOGICAL)

III.A Safety Testing

Pharmacological Studies

As this is a generic application according to Article 13, and bioequivalence with a reference product (Paracilline, REG NL 4256) has been demonstrated, results of pharmacological tests are not required.

The pharmacological aspects of this product are identical to the reference product.

Toxicological Studies

As this is a generic application according to Article 13, and bioequivalence with a reference product (Paracilline, REG NL 4256) has been demonstrated, results of toxicological tests are not required.

The toxicological aspects of this product are identical to the reference product.

User Safety

As this is a generic application according to Article 13, and bioequivalence with a reference product (Paracilline, REG NL 4256) has been demonstrated, results of user safety tests are not required.

Additional user safety statements have been added, based on increased knowledge and the current state of science.
Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product.

Ecotoxicity

The applicant provided a first phase environmental risk assessment in compliance with the relevant guideline which showed that further assessment was required. The assessment concluded that the active ingredient rapidly degrades in chicken manure, studies of the degradation product, penicilloic acid, lead to the conclusion that the use of the product will not lead to an environmental risk. No warnings are therefore required.

III.B Residues documentation

Residue Studies

The applicant has conducted residue depletion studies which show that 12 hours after the last administration residue levels in all tissues were below the MRL.

The analytical method was HPLC-MS/MS. The method was fully validated.

MRLs

Amoxicillin is listed in Annex I of Council Regulation 2377/90. The marker substance is amoxicillin.

MRLs are listed below:

	All food producing species
Muscle	50 µg/kg
Liver	50 µg/kg
Kidney	50 µg/kg
Fat / skin	50 µg/kg
Milk	4 µg/kg

Withdrawal Periods

Based on the data provided above, a withdrawal period of 24 hours for meat in chickens is justified.

IV. CLINICAL ASSESSMENT (EFFICACY)

IV.A Pre-Clinical Studies

Tolerance in the Target Species of Animals

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, target animal tolerance studies are not required. The tolerance claims for this product are equivalent to those of the reference product for target species chicken..

The product literature accurately reflects the type and incidence of adverse effects which might be expected.

IV.B Clinical Studies

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, efficacy studies are not required. The efficacy claims for this product are equivalent to those of the reference product for target species chicken.

V . OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.

MODULE 4

POST-AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the Heads of Veterinary Medicines Agencies website (www.HMA.eu).

This section contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

Quality changes

Summary of change **(Application number)**	**Section updated in Module 3**	**Approval date**
Removal of an active substance manufacturer and addition of a new active substance manufacturer (CEP). (NL/V/0144/001/IA/003)	N/A	8 August 2013
Renewal (NL/V/0144/001/R/001)	N/A	29 August 2014
Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State. (NL/V/0144/IA/004/G)	N/A	22 March 2017
• Variation B.II.b.3.a.: minor change in manufacturing process (type IA); • Variation B.III.1.a.2: Updated certificate from an already approved manufacturer - Sandoz Industrial Products S.A (type IA); • Variation B.III.1.a.2: Updated certificate from an already approved manufacturer - Zhuhai United Laboratories Co., Ltd. (type IA); • Variation B.III.1.a.3: New certificate from a new manufacturer (replacement or addition), type IAIN. (replacement Oman to The United Laboratories Co. (Inner Mongolia Zhuhai)). • Variation B.I.d.1.a.4) : Extension or introduction of a re-test period/storage period supported by real time data - For the re-test period of 4 years for The United Laboratories Co.(Type IB) (NL/V/xxxx/WS/013)	N/A	30 September 2018